ASCENDIS HEALTH LIMITED - Statement in respect of the article presented on Bloomberg and in Business Day and further cautionary announcement

Statement in respect of the article presented on Bloomberg and in Business Day and further cautionary announcement

 Ascendis Health Limited
 (Registration number 2008/005856/06)
 (Incorporated in the Republic of South Africa)
 Share code: ASC
 ISIN: ZAE000185005
 (“Ascendis” or “the Company”)


 Statement in respect of the article presented on Bloomberg and in Business Day and further
 cautionary announcement

 Shareholders are referred to the article published on Bloomberg following market close yesterday,
 7 February 2109, and in the Business Day today, 8 February 2019, titled “Ascendis ‘plans further unit
 sales’ to reduce debt” (“the Article”).

 The Article contained details in respect of, inter alia, the proposed disposal by the Company of its
 Biosciences business unit and the unsolicited offer received by the Company in respect of its
 Remedica business unit.

 Shareholders are referred to the previous announcements made by the Company in this regard,
 specifically -
  -   the announcement released by the Company on the Stock Exchange News Service (“SENS”) on
      25 September 2018, relating to the strategic review of the Ascendis business, in which
      announcement the Company advised that, inter alia, its Biosciences business unit had been
      identified as non-core to the longer-term strategy of the Company and accordingly identified for
      divestment; and
 -    the cautionary announcement released by the Company on SENS on 14 January 2019, regarding
      the receipt by the Company of an unsolicited offer in respect of its Remedica business unit
      (“the Remedica Offer”).

Shareholders are further advised that the information set out in the Article pertaining to the valuation of
the Remedica business by Ascendis is unsubstantiated and that the board of directors of Ascendis is
still involved in negotiations regarding the Remedica Offer, the outcome of which may have an effect
on the price of the Company’s securities.

As such, shareholders are advised to continue to exercise caution when dealing in the Company’s
securities until a further announcement is made.


 Bryanston
 8 February 2019

 Sponsor and Corporate Advisor
 Questco Corporate Advisory Proprietary Limited

Date: 08/02/2019 01:31:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.